Rivoceranib

DRUG9 trials

Conditions

Adenoid Cystic CarcinomaAdvanced Hepatocellular Carcinoma (HCC)Gastric AdenocarcinomaGastric CancerGastroesophageal Junction AdenocarcinomaHealthyMetastatic Colorectal CancerMetastatic Olfactory Neuroblastoma

Phase 1

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

TerminatedNCT03707028

Elevar TherapeuticsGastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2018-10-01End: 2021-08-24Updated: 2022-04-11

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

TerminatedNCT04073615

Elevar TherapeuticsMetastatic Colorectal Cancer

Start: 2019-11-18End: 2023-05-31Updated: 2024-05-02

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

CompletedNCT05287360

Elevar TherapeuticsHealthy

Start: 2021-12-30End: 2022-03-24Updated: 2022-04-18

Phase 2

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

TerminatedNCT04119453

Elevar TherapeuticsAdenoid Cystic Carcinoma

Start: 2020-01-22End: 2023-06-28Updated: 2024-06-24

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

Not yet recruitingNCT06200233

Samsung Medical CenterThymic Epithelial Tumor

Start: 2024-05-01End: 2026-12-01Target: 40Updated: 2024-04-09

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

WithdrawnNCT06308575

M.D. Anderson Cancer CenterMetastatic Olfactory Neuroblastoma, Recurrent Olfactory Neuroblastoma

Start: 2024-11-01End: 2024-11-05Updated: 2025-01-10

Phase 3

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

CompletedNCT03042611

Elevar TherapeuticsGastric Adenocarcinoma, Gastric Cancer

Start: 2017-03-14End: 2020-09-23Updated: 2022-07-08

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

TerminatedNCT04985136

Jiangsu HengRui Medicine Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2021-09-26End: 2021-12-29Updated: 2022-09-01

Unknown Phase

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruitingNCT07147101

Fudan UniversityAdvanced Hepatocellular Carcinoma (HCC)

Start: 2025-09-01End: 2028-09-01Target: 150Updated: 2025-08-28

Gastric Cancer2024-01-289 citations

Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

Journal of Clinical Oncology2023-06-013 citations

Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bioequivalence of four formulations of oral rivoceranib tablets in healthy subjects.

Journal of Clinical Oncology2023-06-01

A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

Journal of Clinical Oncology2022-06-019 citations

A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.

Journal of Clinical Oncology2020-05-202 citations

2020-03-0416 citations

A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.

Journal of Clinical Oncology2017-05-204 citations